-
MDM1, p53, and Chemoradiotherapy Response in CRC
2026-09-22
The 2025 Cancer Biology & Medicine study identifies MDM1 as both a potential biomarker and mechanistic regulator of chemoradiotherapy sensitivity in colorectal cancer. Its experiments connect MDM1 overexpression with reduced YBX1 binding at the TP53 promoter, increased p53 expression, and enhanced apoptosis, suggesting a framework for patient stratification and resistance research.
-
When Blocking Apoptosis Clarifies Cancer Biology
2026-09-22
Z-VAD-FMK can do more than suppress apoptotic readouts: it can help translational researchers test whether caspase-dependent death is causal, consequential, or incidental in cancer models. This article connects mechanistic biology, assay strategy, and product selection to findings from ovarian cancer-associated muscle wasting research.
-
Berberrubine and Urate Transporter Regulation in HUA
2026-09-21
The reference study shows that berberrubine reduces chemically induced hyperuricemia in mice through coordinated effects on urate production, renal transporter expression, inflammation, and JAK2/STAT3 signaling. Its value lies in connecting serum urate lowering with renal protection and mechanistic biomarker analysis, while its short-term animal design limits direct clinical translation.
-
Erastin Ferroptosis Workflows for Cancer Research
2026-09-21
Erastin provides an upstream redox-stress challenge for testing cystine metabolism, lipid peroxidation, and genotype-linked tumor vulnerability. This practical guide combines a 10 μM, 24-hour starting workflow with orthogonal validation and translates melanocyte ferroptosis findings into better assay design.
-
Neuroligin 1, PKC, and Repetitive Behavior
2026-09-20
This Advanced Science study identifies a cell-type-specific mechanism linking Neuroligin 1 loss in dorsal-striatal D2 medium spiny neurons to autistic-like self-grooming and digging. Its combination of behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation implicates excessive PKC signaling as a modifiable contributor rather than a standalone explanation for repetitive behavior.
-
Necrostatin 2 (Nec-2): Assay Guide
2026-09-19
A scenario-based guide to using Necrostatin 2 (Nec-2), SKU A3652, to separate necroptosis-related viability loss from nonspecific cytotoxicity. It covers assay controls, compound handling, protocol optimization, interpretation, and practical product-selection criteria.
-
PR-619: Practical DUB Inhibition Workflow
2026-09-18
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for examining ubiquitinated-protein accumulation without directly blocking proteasomal catalytic activity. It is suitable for controlled cell-based ubiquitination and autophagy experiments, but its broad target profile, low-micromolar cytotoxicity, and limited product-dossier evidence require concentration-response testing and parallel viability controls.
-
1-methyl Adenosine: Assay Workflows & Uses
2026-09-18
1-methyl Adenosine supports both mechanistic cell experiments and targeted nucleoside biomarker discovery. Its strongest use-case is a rigorously separated, isotope-diluted LC–MS/MS workflow that distinguishes low-abundance 1-methyl Ado from isomeric RNA metabolites.
-
Oteseconazole (VT-1161): CYP51 Selectivity & Use
2026-09-17
Oteseconazole, also known as VT-1161, is a selective tetrazole CYP51 inhibitor with potent in vitro activity against multiple Candida species. Its strongest evidence supports Candida-focused research and the prevention of recurrent vulvovaginal candidiasis, while activity against Aspergillus fumigatus is limited.
-
Ac-YVAD-CMK for Reliable Pyroptosis Assays
2026-09-17
Learn how Ac-YVAD-CMK (SKU C4810) can help separate caspase-1-dependent cytokine maturation from membrane injury in viability, inflammation, and pyroptosis assays. This scenario-based guide covers controls, formulation, interpretation, and practical product-selection criteria.
-
MK-8745: A Context-Aware Aurora A Workflow
2026-09-16
MK-8745 is a potent and selective Aurora A inhibitor for dissecting mitotic control, apoptosis, and tumor vulnerability. This article translates retinoblastoma findings into practical assay decisions across cell-based and xenograft research while clarifying model selection, endpoint timing, and interpretation limits.
-
Chicken Gasdermins Reveal Caspase-Driven Pyroptosis
2026-09-16
The reference study defines a previously undercharacterized avian pyroptosis pathway by showing that chicken gasdermin A and gasdermin E are cleaved by distinct caspases and that their amino-terminal fragments can damage membranes and restrict bacterial growth. Its combination of biochemical cleavage mapping, cell-based pore-function assays, and infection models provides a framework for studying species-specific gasdermin biology while highlighting the limits of directly transferring mammalian inflammasome models to birds.
-
Auranofin and Metabolic Stress in HCC Research
2026-09-15
Auranofin is a thioredoxin reductase inhibitor that can help researchers interrogate the relationship between redox control and metabolic plasticity in hepatocellular carcinoma. This article translates recent FOXO3/YAP findings into a rigorous, redox-aware assay strategy without overstating unvalidated mechanisms.
-
CHIR-99021 for Stem Cell and Organoid Workflows
2026-09-15
CHIR-99021 (CT99021) provides reversible, selective GSK-3α/β control for tuning pluripotency, endodermal patterning, and organoid maturation. This guide translates atlas-based developmental benchmarking into practical dosing, assay design, and troubleshooting strategies.
-
CCG-1423: A Pathway-Resolved Assay Strategy
2026-09-14
CCG-1423 is a RhoA inhibitor that helps separate MRTF-A transcriptional signaling from ROCK-dependent cytoskeletal remodeling. This article translates recent RhoA/ROCK pathway findings into a practical, evidence-aware framework for cancer research, apoptosis assay design, and cross-domain interpretation.